Individuals Discontinuing Anti-Obesity Injections Put On Weight at a Quadrupled Rate Compared to Those on Conventional Diets

Fresh analysis suggests that individuals who discontinue new slimming jabs like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who halt traditional lifestyle regimens.

Published data in a major health publication demonstrates that while overweight people can lose a large proportion of their total mass while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.

"Users using these drugs need to be informed of the danger of rapid weight regain when the medication is stopped," warns researcher Dr. Susan Jebb.

This pace of regain implies a return to pre-treatment mass in about one and a half years.

Weighing Approaches

The analysis, which examined 37 of studies involving thousands of participants, compared the effects of these new drugs with conventional dieting.

Scientists point out that people who shed pounds through dieting generally experience a slower creep back—approximately 100 grams monthly—once they finish.

Understanding the Quick Regain

Experts propose the mechanism of the jabs explains the heightened weight return.

GLP-1 drugs copy a body's own chemical called GLP-1, which controls hunger.

"Long-term administration of GLP-1 levels several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.

"Discontinuation of this hormone supplement means hunger is unsuppressed, making excessive eating far more likely."

A Lifelong Disease?

The NHS suggest the jabs for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.

A number of clinicians say that, considering the high risk of weight regain, the treatment is often ongoing.

This perspective is reinforced by drug manufacturers, who note that the findings "underscore the persistent character of excess weight," similar to managing conditions like hypertension.

User Experiences

Users who have stopped the jabs explain a powerful resurgence of hunger.

"It felt as if something flipping and you become ravenous," recalled an individual.

This difficulty is exacerbated if users have not developed permanent dietary or behavioural changes during therapy.

Widespread Adoption

Figures suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.

• Adoption is higher among women than men.
• The 40s and 50s demographic shows the greatest level of interest.
• Many access the drugs through private healthcare rather than public health services.

In conclusion, clinicians emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent cure and long-term success hinges on integrated lifestyle support.